Clinical Trials Logo

Clinical Trial Summary

The research studies the safety and efficacy of high-dose recombinant human TPO in solid tumor patients with moderate or severe thrombocytopenia induced by chemotherapy. Patients with platelet count lower than 50 x 109/L will be enrolled and treated with high-dose rhTPO (300-600U/kg/day) until the platelets increased by 50 x 109/L compared to the baseline or above 100 x 109/L. During the study, the blood routine test will be regularly performed according to the clinical routine (at least once every two days). Finally, the clinical data will be collected and analyzed to validate the efficacy and safety of high-dose rhTPO therapy.


Clinical Trial Description

Chemotherapy-induced thrombocytopenia is a common toxic reaction of chemotherapeutic drugs, which may lead to dose reduction, delay or even termination of chemotherapy. Severe thrombocytopenia may cause bleeding and threaten patient's life. rhIL-11 and rhTPO are the only two drugs approved by China Food and Drug Administration for the treatment of chemotherapy-induced thrombocytopenia. The recommended dosage of rhTPO is 300U/kg. Clinical practice in the real world is full of changes and restraints. In the treatment of thrombocytopenia induced by chemotherapy, the actual dose of rhTPO is often below 300U/kg, due to factors such as Specs, economy and convenience. If the dose of rhTPO is insufficient, it can not give full play to the effect and thus can not achieve the purpose of rapid recovery of platelets. Previous clinical studies observed that the effect of rhTPO depends on the given dose. Dosage in the range of 75U-600U/kg of rhTPO were safe in human. While the 75U/kg dose group had no significant effect on the platelet count elevation, the platelet count in other three dose groups of 150U/kg, 300U/kg and 600U/kg increased by 24%, 32%, and 52% (P < 0.01). This research is a real-world study designed to verify the safety and efficacy of high-dose rhTPO in solid tumor patients with moderate or severe thrombocytopenia induced by chemotherapy. Patients with platelet count lower than 50 x 109/L will be enrolled and treated with high-dose rhTPO (300-600U/kg/day) until the platelets increased by 50 x 109/L compared to the baseline or above 100 x 109/L. During the study, the blood routine test will be regularly performed according to the clinical routine (at least once every two days) and the clinical data will be collected and analyzed. It is based on the patient's actual condition and the treatment measure is more consistent with the clinical practice. The results of this study are expected to provide new options and references for clinical treatment of thrombocytopenia induced by chemotherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03633019
Study type Interventional
Source First Affiliated Hospital Xi'an Jiaotong University
Contact Lingxiao Zhang, doctor
Phone +8618066910386
Email 514324869@qq.com
Status Recruiting
Phase Phase 4
Start date September 28, 2018
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT06087198 - Clinical Performance Evaluation of T-TAS®01 HD Chip
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Active, not recruiting NCT03688191 - Study of Sirolimus in CTD-TP in China Phase 4
Completed NCT02845609 - Efficacy of Sialic Acid GNE Related Thrombocytopenia Phase 2
Recruiting NCT02241031 - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia Phase 2/Phase 3
Recruiting NCT02244658 - Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia Phase 3
Terminated NCT01368211 - Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study) Phase 2/Phase 3
Completed NCT01356576 - Effect of Hemodialysis Membranes on Platelet Count N/A
Unknown status NCT01196884 - Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
Completed NCT00039858 - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Phase 4
Completed NCT00787241 - Platelet Count Trends in Pre-eclamptic Parturients N/A
Completed NCT00001533 - Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine Phase 1
Not yet recruiting NCT06036966 - The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients Phase 2
Completed NCT01791101 - Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia. Phase 2
Recruiting NCT06053021 - Antiplatelet Therapy for AIS Patients With Thrombocytopenia N/A
Recruiting NCT03701217 - Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML Phase 2/Phase 3
Not yet recruiting NCT05958511 - Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients
Completed NCT04917679 - Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP Phase 2